Alpha Tau Medical

Company Overview

Snapshot

Founded in January 2016 by Prof. Itzhak Kelson and Prof. Yona Keisari, Alpha Tau Medical operates with 51–200 employees. The company has raised $201.9 million across 7 funding rounds from 10 investors. In March 2022, Alpha Tau Medical went public on NASDAQ.

Business overview

Alpha Tau Medical is a medical device company specializing in the development and commercialization of its Diffusing Alpha-emitters Radiation Therapy (DaRT) for treating solid cancers. This technology, developed at Tel Aviv University, utilizes alpha-emitting atoms directly inserted into tumors to deliver a high-energy dose over several millimeters, providing focal alpha-radiation while sparing healthy tissue. The company serves the healthcare industry, focusing on oncology, and operates within the medical devices and medical treatment & therapeutics sectors.

Strategic signal

In May 2026, Alpha Tau Medical completed patient enrollment in its U.S. pivotal skin cancer study, a critical step towards achieving FDA approval for its Alpha DaRT® treatment for recurrent cutaneous squamous cell carcinoma. This milestone signals significant progress in the company's clinical development pipeline and its commitment to bringing innovative cancer therapies to market, potentially accelerating its commercial readiness and market access for a key indication.

Company Intelligence Q&A

What is Alpha Tau Medical's core technology?

Alpha Tau Medical's core technology is Diffusing Alpha-emitters Radiation Therapy (DaRT), which uses alpha-emitting atoms directly inserted into solid tumors to deliver a high-energy dose for focal alpha-radiation treatment.

When did Alpha Tau Medical go public?

Alpha Tau Medical went public on NASDAQ in March 2022.

Has Alpha Tau Medical received any FDA designations for its technology?

Yes, Alpha Tau Medical received FDA Breakthrough Device Designation for Alpha DaRT for the treatment of patients with SCC of the skin or oral cavity without curative standard of care, and later for the treatment of recurrent Glioblastoma Multiforme (GBM).

What was a recent clinical milestone for Alpha Tau Medical?

In May 2026, Alpha Tau Medical completed patient enrollment in its U.S. pivotal skin cancer study, advancing towards FDA approval of Alpha DaRT® for recurrent cutaneous squamous cell carcinoma.

What was a recent strategic partnership for Alpha Tau Medical?

In April 2025, Alpha Tau Medical announced an investment and strategic collaboration with Oramed Pharmaceuticals.